Prestige Consumer Healthcare reports record FY23 revenue $1.1277B; guides FY24 EPS $4.27-$4.32

Prestige Consumer Healthcare Inc.

2023-FY EPS reported -$1.65 revenue$1,127,725,000

Q4 revenue $285.9M (+7.1% YoY, +8.0% organic); adjusted EPS $1.07 vs $0.91 prior year.
Full year FY23 revenue $1.1277B (record); net loss $82.3M on impairments; adjusted EPS $4.21.
FY24 guidance: revenue $1.135-$1.140B, diluted EPS $4.27-$4.32, free cash flow $240M+.
Board authorized $25M share repurchase through May 2024.
Covenant leverage ratio 3.3x; new long-term target below 3.0x.

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Prestige Consumer Healthcare Inc. reported the fiscal year ended March 31, 2023 results: revenue $1,127.7 million, net income net loss of $82.3 million, EPS diluted loss per share of $1.65.

Period: the fiscal year ended March 31, 2023
Revenue: $1,127.7 million
Net income: net loss of $82.3 million
EPS: diluted loss per share of $1.65
Result: reported results

Exact text from the filing

Reported revenues for the fiscal year 2023 totaled $1,127.7 million, an increase of 3.8%, compared to revenues of $1,086.8 million for the fiscal year 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Prestige Consumer Healthcare Inc. reported Fiscal 2024 results: revenue $1,135 to $1,140 Million, EPS $4.27 to $4.32. Guidance initiated.

Period: Fiscal 2024
Revenue: $1,135 to $1,140 Million
EPS: $4.27 to $4.32
Guidance: initiated
Result: guidance update

Exact text from the filing

Initial Full-Year Fiscal 2024 Revenue and EPS Expectation of $1,135 to $1,140 Million and $4.27 to $4.32, respectively

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Prestige Consumer Healthcare Inc. reported the fourth quarter ended March 31, 2023 results: revenue $285.9 million, net income net loss of $240.6 million, EPS diluted loss per share of $4.83.

Period: the fourth quarter ended March 31, 2023
Revenue: $285.9 million
Net income: net loss of $240.6 million
EPS: diluted loss per share of $4.83
Result: reported results

Exact text from the filing

Reported revenues in the fourth quarter of fiscal 2023 of $285.9 million increased 7.1% from $266.9 million in the fourth quarter of fiscal 2022.

View on SEC.gov

Browse all earnings releases →

Prestige Consumer Healthcare Inc. filing history →

Source: SEC EDGAR

accession 0001295947-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.